Trial Profile

A proof-of-concept clinical trial for VRDN-002 in TED patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 14 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VRDN 002 (Primary)
Indications Graves ophthalmopathy
Focus Proof of concept; Therapeutic Use
Sponsors Viridian Therapeutics

Most Recent Events

08 Mar 2023 According to Viridian Therapeutics media release, results are expected by year end 2023.
20 Aug 2022 New trial record
15 Aug 2022 According to Viridian Therapeutics media release, VRDN-002 will advance to a proof-of-concept trial in TED, with data expected in the second half of 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com